Sanne H. Tonino

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial.

Journal: The Lancet. Haematology
Published: December 18, 2025

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA.

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA.

Journal: Blood advances
Published: October 24, 2025

Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study.

Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study.

Journal: HemaSphere
Published: September 05, 2025

A Drop of Blood to Lead the Way.

A Drop of Blood to Lead the Way.

Journal: Hematology reports
Published: July 16, 2025

Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.

Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.

Journal: Current opinion in oncology
Published: June 13, 2025

Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.

Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 11, 2025

Navigating Ethical Challenges in CAR-T Treatment.

Navigating Ethical Challenges in CAR-T Treatment.

Journal: HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
Published: February 03, 2025

High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial.

High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial.

Journal: HemaSphere
Published: November 09, 2024

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.

Journal: Blood neoplasia
Published: April 11, 2024

The quest for a cure in follicular lymphoma.

The quest for a cure in follicular lymphoma.

Journal: Blood
Published: February 08, 2024

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 15, 2023

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Journal: American journal of hematology
Published: June 25, 2023
Showing 1-12 of 55

Last Updated: 09/26/2026